Enveric Biosciences, Inc. (ENVB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Enveric Biosciences reported revenue of $0. Net income was -$8.8M, or -$36.24 per diluted share. Operating activities generated -$8.1M of cash. At fiscal year end, Enveric Biosciences held $5.1M in total assets against $918,400 in total liabilities.
Open the full interactive Enveric Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Enveric Biosciences Key Stats
| Share Price | $1.40 |
|---|---|
| Market Cap | $5.6M |
| 52-Week Range | $1.27 – $10.80 |
| Shares Outstanding | 4.0 million (basic, 2026 Q2) |
Enveric Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$5.6M | -$64.6M | -$27.4M | -$16.4M | -$9.6M | -$8.8M |
| Pre-Tax Income | -$6.9M | -$56.4M | -$20.0M | -$17.3M | -$9.6M | -$8.8M |
| Income Tax | — | -$7.5M | -$1.5M | $28,913 | $8,930 | — |
| Net Income | -$6.9M | -$49.0M | -$18.5M | -$17.3M | -$9.6M | -$8.8M |
| Diluted EPS | -$160650.00 | -$279450.00 | — | -$21843.00 | -$228.48 | -$36.24 |
Enveric Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.9M | -$2.2M | -$1.6M | -$3.0M |
| Diluted EPS | -$10.81 | -$6.56 | -$1.08 | -$0.76 |
Enveric Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Current Assets | $2.3M | $17.7M | $18.4M | $3.6M | $2.7M | $4.9M |
| Total Assets | $4.1M | $26.7M | $19.6M | $4.3M | $3.1M | $5.1M |
| Current Liabilities | — | $2.1M | $4.0M | $2.3M | $1.5M | $918,400 |
| Total Liabilities | $681,250 | $4.4M | $4.0M | $2.3M | $1.5M | $918,400 |
| Shareholders' Equity | $3.4M | $22.3M | $14.7M | $2.0M | $1.6M | $4.2M |
Enveric Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.9M | -$11.5M | -$17.1M | -$14.1M | -$7.7M | -$8.1M |
| Cash From Investing | -$44,143 | $2.2M | -$584,165 | $11,667 | — | — |
| Cash From Financing | $5.5M | $24.9M | $18.2M | -$1.3M | $7.7M | $10.6M |
| Free Cash Flow | — | — | -$17.7M | -$14.1M | -$7.7M | — |
Figures from Enveric Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Enveric Biosciences financials page for every line item.
Enveric Biosciences Company Profile
| Ticker | ENVB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000890821 |
Frequently Asked Questions
What was Enveric Biosciences' revenue in fiscal 2025?
Enveric Biosciences (ENVB) reported revenue of $0 for fiscal 2025.
What is Enveric Biosciences' annual revenue history?
Enveric Biosciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Enveric Biosciences' net income in fiscal 2025?
Enveric Biosciences reported net income of -$8.8M for fiscal 2025.
What was Enveric Biosciences' earnings per share (EPS) in fiscal 2025?
Enveric Biosciences' diluted EPS was -$36.24 for fiscal 2025 (adjusted for any later stock splits).
What was Enveric Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Enveric Biosciences reported revenue of $0.
How many shares of Enveric Biosciences are outstanding?
Enveric Biosciences reported a weighted average of 4.0 million basic shares outstanding in 2026 Q2.
What is Enveric Biosciences' market cap?
Based on its latest closing price, Enveric Biosciences (ENVB) has a market capitalization of about $5.6M.
When does Enveric Biosciences' fiscal year end?
Enveric Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Enveric Biosciences headquartered?
Enveric Biosciences lists its business address in Cambridge, Massachusetts in its SEC filings.